Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population

  • Head and Neck
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Purpose

Salivary gland tumors are rare and include benign and malignant entities with different behavior and prognosis. Salivary gland carcinoma accounts for 0.2% of all cancers and 5–9% of head and neck carcinomas. We aim to describe the clinicopathological characteristics and discuss the immunohistochemical findings of salivary ductal carcinoma.

Methods

We obtained 17 cases (2.3%) of salivary ductal carcinoma (SDC) from 727 patients with parotid tumors at our cancer center from a database covering a 22-year period (1996–2018). Two pathologists confirmed the diagnosis and excluded 6 cases. Eleven cases were assessed by immunohistochemistry (IHC) for HER2, estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), mammaglobin, P53, GATA3, S100, cytokeratins (7,8,14,18, and 20), P63, PAX8, calponin, and SOX10.

Results

Eleven SDC cases were in advanced stage, and 80% had metastasis. All cases were surgically treated, and 40% received different adjuvant chemotherapy regimens. we found that most patients were dead of disease. The histological and immunohistochemical analysis showed that 70% of cases were high-grade, 40% were positive for HER2, and 50% for AR. Moreover, a high Ki-67 proliferative index was detected in all cases. We observed luminal differentiation in 50% of cases.

Conclusion

SDC is a rare entity and survival is very poor. It is histologically similar to ductal carcinoma of the breast. However, important differences exist that help to distinguish them in case of synchronous cancers. The clinical behavior of SDC seems to be more aggressive and IHC analysis is useful for designing therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data, material and/or Code availability

Yes.

References

  1. Mifsud MJ, Burton JN, Trotti AM, Padhya TA (2016) Multidisciplinary management of salivary gland cancer. Cancer Control 23:242–248

    Article  PubMed  Google Scholar 

  2. Seethala RR, Stenman G (2017) Update from 4th edition the of the World Health Organization Classification of the Head and Neck Tumour Tumors of the Salivary Gland. Head Neck Pathol 11:55–67

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mifsud M, Eskander A, Irish J, Gullane P, Gilbert R, Brown D, de Almeida JR, Urbach DR, Goldstein DP (2017) Evolving trends in head and neck cancer epidemiology: Ontario, Canada 1993–2010. Head Neck 39:1770–1778

    Article  PubMed  Google Scholar 

  4. Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, UdDin N, Purgina B, Lai C, Griffith CC, Chiosea SI (2015) Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol 39:705–713

    Article  PubMed  Google Scholar 

  5. Brandwein MS, Jagirdar J, Patil J, Biller H, Kaneko M (1990) Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts) A clinicopathologic and immunohistochemical study of 12 cases. Cancer 65:2307–2314

    Article  CAS  PubMed  Google Scholar 

  6. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 15(103):2526–2533

    Article  Google Scholar 

  7. Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim S (2016) A 20-year review of cases of salivary duct carcinoma. JAMA Otolaryngol Head Neck Surg 142(5):489–495

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533

    Article  PubMed  Google Scholar 

  9. Simpson RHW (2013) Salivary duct carcinoma: new developments-morphological variants including pure in situ high grade lesions; proposed molecular classification. Head Neck Pathol 7:S48–S58

    Article  PubMed  Google Scholar 

  10. Masubuchi T, Tada Y, Maray S, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T (2015) Clinicopathological significance of androgen Receptor, HER2, Ki-67 and EGFR expression in salivary duct carcinoma. Int J Clin Oncol 20:35–44

    Article  CAS  PubMed  Google Scholar 

  11. Kim TH, Kim MS, Choi SH et al (2014) Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience. Radiat Oncol J 32:125–131

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ferreira-Damasceno RW, Holbach LM (2012) Primary ductal adenocarcinoma of the lacrimal gland: case report. Arq Bras Oftalmol 75:64–66

    Article  Google Scholar 

  13. Butler RT, Soector ME, Thomas D, McDaniel AS, McHugh JB (2014) An immunohistochemical panel for reliable differentiation of salivary duct carcinoma and mucoepidermoid carcinoma. Head Neck Pathol 8:133–140

    Article  PubMed  Google Scholar 

  14. Cros J, Sbidian E, Hans S, Roussel H, Scotte F, Tartour E, Brasnu D, Laurent-Puig P, Bruneval P, Blons H, Badoual C (2013) Expression and mutational status of treatment-relevant target and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol 24:2624–2629

    Article  CAS  PubMed  Google Scholar 

  15. William MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK (2007) Differential expression of hormonal and growth factor receptor in salivary duct carcinomas: Biologic significance and potential role in therapeutics stratification of patients. Am J Surg Pathol 31:1645–1652

    Article  Google Scholar 

  16. Jaspers HCJ, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, va der Graaf WT, van Herpen CM (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment option. J Clin Oncol 29:e476–e476

    Article  Google Scholar 

  17. Shahid Iqbal M, Saikh G, Chatterjee S, Cocks H, Kovaril J (2014) Maintenance therapy with trastuzumab in Her2 positive metastatic parotid ductal adenocarcinoma. Case Rep Oncol Med 162534:4. https://doi.org/10.1155/2014/162534

    Article  Google Scholar 

  18. Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39:724–727

    Article  CAS  PubMed  Google Scholar 

  19. Agulnik M, Cohen EWE, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expresssing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978–3984

    Article  CAS  PubMed  Google Scholar 

  20. Demir Y, Suruci E, Durak MG et al (2013) Contralateral parotideal lymph node metastasis detected by PET/CT in female patient with locally advanced breast cancer. Rev Esp Med Nucl Imagen Mol 32:330–331

    CAS  PubMed  Google Scholar 

  21. Jalaly JB, Sanati S, Chernock RD, Dibe DG, El-Mofty S (2018) Salivary duct carcinoma and invasive ductal carcinoma of the breast: a comparative immunohistochemical study. Head Neck Pathol 12:488–492

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors have no relevant financial or non-financial interests to disclose.

Author information

Authors and Affiliations

  1. Department of Head and Neck Surgery, Instituto Nacional de Cancerología (Mexico), Av San Fernando # 22 Col. Sección XVI, Tlalpan, 14080, Mexico City, Mexico

    Kuauhyama Luna-Ortiz, Cesar Herrera-Ponzanelli & Luis C. Zacarias-Ramon

  2. Department of Pathology, Instituto Nacional de Cancerología (Mexico), Av San Fernando # 22 Col. Sección XVI, Tlalpan, 14080, Mexico City, Mexico

    Hugo Dominguez-Malagon & Guillermo E. Corredor-Alonso

  3. Research Department at the Instituto Nacional de Cancerología (Mexico), Av San Fernando # 22 Col. Sección XVI, Tlalpan, 14080, Mexico City, Mexico

    Nancy Reynoso-Noveron

  4. Department of General Surgery (Head and Neck), Hospital Manuel Gea Gonzalez, Mexico City, Mexico

    Kuauhyama Luna-Ortiz

  5. General Medicine, Universitatea de Medicinâ si Farmacie Grigorie T. Popa IASI, Iasi, Romania

    Zelik Luna-Peteuil

Authors
  1. Kuauhyama Luna-Ortiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hugo Dominguez-Malagon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guillermo E. Corredor-Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nancy Reynoso-Noveron
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cesar Herrera-Ponzanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zelik Luna-Peteuil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luis C. Zacarias-Ramon
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation by LCZ-R, data collection by CH-P, ZL-P and analysis were performed by NR-N and KL-O. The first draft of the manuscript was written by KL-O and HD-M and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding acquisition for the present work, none.

Corresponding author

Correspondence to Kuauhyama Luna-Ortiz.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare that are relevant to the content of this article. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. The authors have no financial or proprietary interests in any material discussed in this article.

Ethics approval

This study was reviewed and approved by the Institutional Review Board and registered under the number Rev/033/20.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luna-Ortiz, K., Dominguez-Malagon, H., Corredor-Alonso, G.E. et al. Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population. Eur Arch Otorhinolaryngol 279, 327–333 (2022). https://doi.org/10.1007/s00405-021-06757-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-021-06757-x

Keywords

Search

Navigation